Cargando…

COVID-19: ACT trials for colchicine and antithrombotic therapies

Detalles Bibliográficos
Autores principales:	Barco, Stefano, Schreiber, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550192/ https://www.ncbi.nlm.nih.gov/pubmed/36228642 http://dx.doi.org/10.1016/S2213-2600(22)00368-X

Ejemplares similares

Colchicine treatment in COVID-19: the remaining unsolved question
por: Rojas-Villarraga, Adriana, et al.
Publicado: (2021)

Antithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more
por: Connors, Jean M, et al.
Publicado: (2022)

Reversal of Antithrombotic Therapy: Is it Necessary and Sufficient?
por: Becker, Richard C.
Publicado: (2017)

Women with gout and COVID-19—an unfortunate combination?
por: Nissen, Christoffer B, et al.
Publicado: (2022)

Cessation of antithrombotic therapy before surgery: weighing thrombosis and bleeding risks
por: Meesters, M. I., et al.
Publicado: (2014)

First data on COVID-19 morbidity and mortality in patients with rheumatic disease from South Korea
por: Schreiber, Karen, et al.
Publicado: (2021)

Child malnutrition and COVID-19: the time to act is now
por: Fore, Henrietta H, et al.
Publicado: (2020)

Gender equality and COVID-19: act now before it is too late
por: Morgan, Rosemary, et al.
Publicado: (2022)

Living with the COVID-19 pandemic: act now with the tools we have
por: Bedford, Juliet, et al.
Publicado: (2020)

Looming threat of COVID-19 infection in Africa: act collectively, and fast
por: Nkengasong, John N, et al.
Publicado: (2020)

Stacking of antithrombotic drugs in cardiology: evidence-based customisation
por: Peters, R. J. G.
Publicado: (2022)

Antithrombotic therapy in COVID-19
por: Saeed, Sahrai, et al.
Publicado: (2021)

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
por: Feldmann, Marc, et al.
Publicado: (2020)

Proposed recommendations for antithrombotic prophylaxis for children and adolescents with severe infection and/or multisystem inflammatory syndrome caused by SARS-CoV-2
por: Carneiro, Jorge David Aivazoglou, et al.
Publicado: (2020)

Antithrombotic treatment in atrial fibrillation patients needing percutaneous coronary intervention
por: Huisman, M. V.
Publicado: (2021)

Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
por: Eikelboom, John W, et al.
Publicado: (2022)

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
por: Robinson, Philip C, et al.
Publicado: (2020)

COVID-19, community trials, and inclusion
por: Gill, Paramjit S, et al.
Publicado: (2021)

Passive antibody therapy in COVID-19
por: Abraham, Jonathan
Publicado: (2020)

Anticoagulation in COVID-19: reaction to the ACTION trial
por: Berger, Jeffrey S, et al.
Publicado: (2021)

The balancing act of urban conservation
por: Turo, Katherine J., et al.
Publicado: (2020)

Intravenous immunoglobulin therapy for COVID-19 ARDS
por: Wilfong, Erin M, et al.
Publicado: (2022)

COVID-19: immunopathology and its implications for therapy
por: Cao, Xuetao
Publicado: (2020)

Vitamin D Insufficiency May Account for Almost Nine of Ten COVID-19 Deaths: Time to Act. Comment on: “Vitamin D Deficiency and Outcome of COVID-19 Patients”. Nutrients 2020, 12, 2757
por: Brenner, Hermann, et al.
Publicado: (2020)

Stewardship of COVID-19 volunteers by nested trial design
por: Gottlieb, Robert L, et al.
Publicado: (2022)

Rethinking cancer clinical trials for COVID-19 and beyond
por: Doherty, Gary J., et al.
Publicado: (2020)

PIONEER trial: favipiravir to treat moderate COVID-19
por: Shalhoub, Sarah
Publicado: (2023)

COVID-19 vaccinations for children
por: Mariatulqabtiah, Abdul Razak, et al.
Publicado: (2022)

CD24Fc: an emerging COVID-19 therapy
por: Eckhardt, Christina M, et al.
Publicado: (2022)

No perfect therapy for the imperfect COVID-19 cytokine storm
por: Cron, Randy Q
Publicado: (2022)

Electroconvulsive therapy practice during the COVID-19 pandemic
por: Bellini, Helena, et al.
Publicado: (2020)

Convalescent plasma as a potential therapy for COVID-19
por: Chen, Long, et al.
Publicado: (2020)

Kidney involvement in COVID-19 and rationale for extracorporeal therapies
por: Ronco, Claudio, et al.
Publicado: (2020)

COVID-19 and systemic anticancer therapy: exploiting uncertainty
por: Gelderblom, Hans, et al.
Publicado: (2021)

Offline: ACT-A—ça suffit
por: Horton, Richard
Publicado: (2023)

Digital mental health care: five lessons from Act 1 and a preview of Acts 2–5
por: Insel, Thomas
Publicado: (2023)

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
por: Eikelboom, John W, et al.
Publicado: (2022)

The COVID-19 pandemic: a catalyst to improve clinical trials
por: Gaba, Prakriti, et al.
Publicado: (2020)

COVID-19 vaccine trials should seek worthwhile efficacy
por: Krause, Philip, et al.
Publicado: (2020)

Mitigating the impacts of COVID-19: where are the mental health trials?
por: Gilbody, Simon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tqttj9ftgemk2cs6llm5uis1tf